10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
11.73
+0.03 (0.26%)
At close: Jun 27, 2025, 4:00 PM
11.62
-0.11 (-0.94%)
After-hours: Jun 27, 2025, 7:43 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 13 professional analysts, the 12-month price target for 10x Genomics stock ranges from a low of $6.50 to a high of $25. The average analyst price target of $14.96 forecasts a 27.54% increase in the stock price over the next year.
Price Target: $14.96 (+27.54%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 7 | 8 | 8 | 8 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 16 | 16 | 16 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | +10.83% | Jun 26, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +10.83% | Jun 24, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $26 → $18 | Buy | Maintains | $26 → $18 | +53.45% | May 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $14 | Buy | Reiterates | $14 | +19.35% | May 15, 2025 |
| UBS | UBS | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +2.30% | May 13, 2025 |
Financial Forecast
Revenue This Year
595.41M
from 610.79M
Decreased by -2.52%
Revenue Next Year
631.51M
from 595.41M
Increased by 6.06%
EPS This Year
-1.22
from -1.52
EPS Next Year
-0.94
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 640.5M | 703.8M | 805.7M | ||
| Avg | 595.4M | 631.5M | 687.7M | ||
| Low | 560.2M | 569.4M | 614.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.9% | 18.2% | 27.6% | ||
| Avg | -2.5% | 6.1% | 8.9% | ||
| Low | -8.3% | -4.4% | -2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.46 | -0.02 | ||
| Avg | -1.22 | -0.94 | -0.69 | ||
| Low | -1.48 | -1.23 | -1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.